POLYMED - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | POLYMED | Market Cap | 13,467 Cr. | Current Price | 1,329 ₹ | High / Low | 2,387 ₹ |
| Stock P/E | 39.5 | Book Value | 301 ₹ | Dividend Yield | 0.26 % | ROCE | 15.0 % |
| ROE | 11.8 % | Face Value | 5.00 ₹ | DMA 50 | 1,483 ₹ | DMA 200 | 1,675 ₹ |
| Chg in FII Hold | -3.49 % | Chg in DII Hold | 1.76 % | PAT Qtr | 80.6 Cr. | PAT Prev Qtr | 83.4 Cr. |
| RSI | 36.3 | MACD | -5.11 | Volume | 6,06,696 | Avg Vol 1Wk | 3,53,908 |
| Low price | 1,182 ₹ | High price | 2,387 ₹ | PEG Ratio | 1.54 | Debt to equity | 0.08 |
| 52w Index | 12.2 % | Qtr Profit Var | -6.97 % | EPS | 33.2 ₹ | Industry PE | 32.5 |
📊 Optimal Buy Price (Intraday): ₹1,300–1,320 (near support zone, below 50 DMA at ₹1,483)
🎯 Profit-Taking Levels: ₹1,360–1,380 (short-term resistance zone, far below 200 DMA at ₹1,675)
🛡️ Stop-Loss / Loss Protection: ₹1,280–1,285 (below intraday support zone)
⏱️ Exit Strategy (If Already Holding): Exit if price fails to sustain above ₹1,285 with weakening volume, or book profits if RSI approaches 38–40 and momentum flattens. Extend trades only if breakout above ₹1,380–1,400 is confirmed with strong intraday volume.
---
### Positive
- EPS at ₹33.2 supports valuation strength.
- ROCE (15.0%) and ROE (11.8%) indicate moderate efficiency.
- Debt-to-equity at 0.08 shows low leverage risk.
- Volume (6.06 lakh) above weekly average (3.53 lakh), providing strong intraday liquidity.
- DII holding increased (+1.76%), reflecting domestic institutional confidence.
### Limitation
- RSI at 36.3 indicates weak momentum, near oversold territory.
- MACD negative (-5.11) signals bearish bias.
- Current price (₹1,329) below both DMA 50 (₹1,483) and DMA 200 (₹1,675), showing technical weakness.
- PAT declined sequentially (₹83.4 Cr. → ₹80.6 Cr.), showing earnings pressure.
- P/E (39.5) above industry average (32.5), showing valuation premium.
- 52-week index at 12.2% highlights weak relative performance.
### Company Negative News
- FII holding reduced (-3.49%), showing foreign investor caution.
- Sequential PAT decline highlights short-term weakness.
### Company Positive News
- DII holding increased (+1.76%), supporting sentiment.
- EPS stability despite profit decline.
### Industry
- Medical devices & healthcare sector benefits from global demand expansion.
- Industry PE at 32.5 is lower than POLYMED’s, highlighting valuation premium.
### Conclusion
POLYMED is a cautious intraday candidate with weak momentum and declining profits but strong liquidity and moderate fundamentals. Best suited for disciplined trades between ₹1,300–1,380 with strict stop-loss at ₹1,285. Avoid aggressive positions unless breakout above ₹1,380–1,400 is confirmed with strong volume; risk remains elevated due to weak technicals and valuation premium.
Would you like me to extend this into a peer benchmarking HTML overlay comparing POLYMED’s intraday setup against Narayana Hrudayalaya, Medanta, and Apollo Hospitals for sector-relative positioning?